PACB
Pacific Biosciences of California, Inc.
$9.61
Earnings Summary
Revenue | $17.08Mn |
Net Profits | $-23.09Mn |
Net Profit Margins | -135.19% |
Highlights
Pacific Biosciences of California, Inc.’s revenue fell -30.64% since last year same period to $17.08Mn in the Q2 2020. On a quarterly growth basis, Pacific Biosciences of California, Inc. has generated 9.48% jump in its revenue since last 3-months.
Pacific Biosciences of California, Inc.’s net profit jumped 6.14% since last year same period to $-23.09Mn in the Q2 2020. On a quarterly growth basis, Pacific Biosciences of California, Inc. has generated -1929.32% fall in its net profits since last 3-months.
Pacific Biosciences of California, Inc.’s net profit margin fell -35.33% since last year same period to -135.19% in the Q2 2020. On a quarterly growth basis, Pacific Biosciences of California, Inc. has generated -1770.89% fall in its net profit margins since last 3-months.
Earnings per share (EPS) Estimates
Earnings per share (EPS) estimates of the Pacific Biosciences of California, Inc. post its latest quarter earnings
EPS Estimate Current Quarter | -0.35 |
EPS Estimate Current Year | -0.35 |
Highlights
Pacific Biosciences of California, Inc.’s earning per share (EPS) estimates for the current quarter stand at -0.35 - a -6.06% fall from last quarter’s estimates.
Pacific Biosciences of California, Inc.’s earning per share (EPS) estimates for the current year stand at -0.35.
Key Ratios
Key ratios of the Pacific Biosciences of California, Inc. post its Q4 2022 earnings
Return on Assets (ROA) | -0.1 |
Return on Equity (ROE) | -0.46 |
Highlights
Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Pacific Biosciences of California, Inc.’s return on assets (ROA) stands at -0.1.
The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Pacific Biosciences of California, Inc.’s return on equity (ROE) stands at -0.46.
Earnings Calendar
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2016-08-04 | -0.22 | -0.21 | 4.55% |
2016-11-04 | -0.2 | -0.19 | 5% |
2016-05-05 | -0.25 | -0.23 | 8% |
2017-03-06 | -0.23 | -0.21 | 8.7% |
Company Information
Pacific Biosciences of California, Inc. is empowering life scientists with highly accurate long-read sequencing. The company's innovative instruments are based on Single Molecule, Real-Time (SMRT®) Sequencing technology, which delivers a comprehensive view of genomes, transcriptomes, and epigenomes, enabling access to the full spectrum of genetic variation in any organism. Cited in thousands of peer-reviewed publications, PacBio® sequencing systems are in use by scientists around the world to drive discovery in human biomedical research, plant and animal sciences, and microbiology.
Organisation | Pacific Biosciences of California, Inc. |
Headquarters | 1305 O?Brien Drive, Menlo Park, CA, United States, 94025 |
Employees | 769 |
Industry | Health Technology |
